Utility of serum procalcitonin for screening and risk stratification of medullary thyroid cancer

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 8, 2014, Pages 2986-2994

  Machens, Andreas ^a   Lorenz, Kerstin ^a   Dralle, Henning ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; CALCITONIN; EARLY DETECTION OF CANCER; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; RETROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84905822489     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2014-1278     Document Type: Article

References (26)

1. Camacho CP, Lindsey SC, Melo MC, et al. Measurement of calcitonin and calcitonin gene-related peptide mRNA refines the management of patients with medullary thyroid cancer and may replace calcitonin-stimulation tests. Thyroid. 2013;23:308-316.
2. Frank-Raue K, Machens A, Leidig-Bruckner G, et al. Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma. Thyroid. 2013;23:294-300.
3. Tashjian AH Jr, Melvin EW. Medullary carcinoma of the thyroid gland. Studies of thyrocalcitonin in plasma and tumor extracts. N Engl J Med. 1968;279:279-283.
4. Machens A, Dralle H. Biomarker-based risk stratification for previously untreated medullary thyroid cancer. J Clin Endocrinol Metab. 2010;95:2655-2663.
5. Yip DT, HassanM, Pazaitou-Panayiotou K, et al. Preoperative basal calcitonin and tumor stage correlate with postoperative calcitonin normalization in patients undergoing initial surgical management of medullary thyroid carcinoma. Surgery. 2011;150:1168-1177.
6. Machens A, Dralle H. Prognostic impact of N staging in 715 medullary thyroid cancer patients: proposal for a revised staging system. Ann Surg. 2013;257:323-329.
7. Machens A, Dralle H. Benefit-risk balance of reoperation for persistent medullary thyroid cancer. Ann Surg. 2013;257:751-757.
8. Algeciras-Schimnich A, Preissner CM, Theobald JP, Finseth MS, Grebe SK. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab. 2009;94:861-868.
9. Kratzsch J, Petzold A, Raue F, et al. Basal and stimulated calcitonin and procalcitonin by various assays in patients with and without medullary thyroid cancer. Clin Chem. 2011;57:467-474.
10. Machens A, Schneyer U, Holzhausen HJ, Dralle H. Prospects of remission in medullary thyroid carcinoma according to basal calcitonin level. J Clin Endocrinol Metab 2005;90:2029-2034.
11. Bieglmayer C, Vierhapper H, Dudczak R, Niederle B. Measurement of calcitonin by immunoassay analyzers. ClinChemLabMed. 2007; 45:662-666.
12. Bieglmayer C, Scheuba C, Niederle B, Flores J, Vierhapper H. Screening for medullary thyroid carcinoma: experience with different immunoassays for human calcitonin. Wien Klin Wochenschr. 2002;114:267-273.
13. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today. 1994;24:112-121.
14. Dralle H. Lymph node dissection and medullary thyroid carcinoma. Br J Surg. 2002;89:1073-1075.
15. Dralle H. Malignant thyroid tumors [in German]. In: Garbe C, Albers P, Beckmann MW, et al, eds. Abbreviated Interdisciplinary Guidelines 2006. Recommendations for Diagnosis and Therapy of Malignant Diseases. W. Munich, Germany: Zuckschwerdt Verlag; 2006.
16. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. In:International Histological Classification of Tumours . 2nd ed. Geneva: World Health Organization; 1988.
17. DeLellis RA Lloyd RV, Heitz PU, Eng C, eds. World Health Orga nization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press; 2004.
18. Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. Clin Chem Lab Med. 2013;51:1477-1481.
19. Giovanella L, Maffioli M, Suriano S, Dorizzi RM. Elevated calcitonin and procalcitonin levels in nonmedullary benign and malignant thyroid nodules. Clin Endocrinol (Oxf). 2010;72:852-853.
20. Walter MA, Meier C, Radimerski T, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. Cancer. 2010;116:31-40.
21. Machens A, Hoffmann F, Sekulla C, Dralle H. Importance of gender- specific calcitonin thresholds in screening for occult sporadic medullary thyroid cancer. Endocr Relat Cancer. 2009;16:1291-1298.
22. Bihan H, Becker KL, Snider RH, et al. Calcitonin precursor levels in human medullary thyroid carcinoma. Thyroid. 2003;8:819-822.
23. Kaczka K, Mikosiński S, Fendler W, Celnik A, Pomorski L. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection. Adv Clin Exp Med. 2012;21:169-178.
24. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005: 97:1180-1184.
25. Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol. 2009;27:4027-4034.
26. Bugalho MJ, Madureira D, Domingues R, Pereira T, Cortez L. Medullary thyroid carcinoma preferentially secreting procalcitonin. Thyroid. 2014;24:1190-1191.